People with Parkinson’s disease exhibit an interplay between the loss of dopamine-producing neurons and overall nerve cell connections, or synapses, in two key brain regions that is distinct from that seen in individuals without the disease, according to a recent study. Researchers demonstrated that in Parkinson’s,…
News
The Parkinson’s Foundation has published a new journal article outlining a practical pathway for making hospital care more age friendly for older people living with Parkinson’s disease. The work aims to translate — into everyday practices — the Age-Friendly Hospital Measure set forth by the Centers for Medicare…
Aerobic exercise may help alleviate motor symptoms and reduce anxiety in early Parkinson’s disease, but there’s a chance higher-intensity workouts may do more harm than good, a mouse study suggested. The results show that “a broad range of symptoms should be assessed in clinical studies with different exercise…
An analysis of electronic health records from 11.3 million U.S. veterans suggests obstructive sleep apnea nearly doubles the risk of developing Parkinson’s disease. But early treatment with continuous positive airway pressure (CPAP), the standard therapy for the condition, may cut that risk by about 30%, the study found, “If…
Cure Parkinson’s and France Parkinson have joined forces to launch a new international initiative, the Global Alliance for Parkinson’s Platforms (GAPP). This alliance brings together leaders from around the world to unite their efforts in running platform trials. This approach simultaneously tests potential disease-modifying treatments for Parkinson’s…
A wrist-worn device may provide a clearer and more consistent picture of tremor in Parkinson’s disease than what can be seen during a single clinic visit or recalled from memory alone, a study has found, adding to evidence that wearable sensors can help track motor symptoms in daily…
Early treatment with the investigational small molecule golexanolone improved motor and cognitive function and eased signs of fatigue, anxiety, and depression in a rat model of Parkinson’s disease. The Umecrine Cognition treatment also reduced neuroinflammation and improved dopamine levels, a study found. Golexanolone “could be considered for clinical evaluation…
The Michael J. Fox Foundation (MJFF) has awarded a $2 million grant to Enigma Biomedical USA for the development and first preclinical testing of a new positron emission tomography (PET) tracer that targets harmful clumps of the protein alpha-synuclein, a hallmark and suspected driver of Parkinson’s disease. The…
Vincere Biosciences won a $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance development of USP30 small molecule inhibitors, its candidate therapy aimed at slowing or halting Parkinson’s disease progression. The grant, provided through MJFF’s Therapeutics Pipeline Program, will…
The American Parkinson Disease Association (APDA) has announced three recipients of its inaugural Bridge Funding Awards, a program designed to support promising Parkinson’s disease research when unexpected gaps in funding occur. The awards were open specifically to researchers APDA has funded within the…
Recent Posts
- First patient in US trial gets new off-the-shelf cell therapy for Parkinson’s
- When I became the unofficial offensive line in Parkinson’s quiet game
- The GPS of Theseus: Training the body’s navigation system with Parkinson’s
- New study highlights UTI risks in hospitalized Parkinson’s patients
- New exercise tips aim to help people with Parkinson’s stay active